TABLE IV.

Correlation of the expression levels of PGAP3, GSDMB, or GSDMA and asthma phenotypes in SARP

RNAseq (156 BEC) in the longitudinal cohort
Gene	Asthma Susceptibility			Asthma Severity			Number of Exacerbations (last 12 months)		ΔACQ6 (After-Before steroid trt)
	Healthy Controls (n=42)	Asthma (n=114)	P value	Non-severe Asthma (n=49)	Severe Asthma (n=65)	P value	Correlation Coefficient (β)	P value (n=114)	Correlation Coefficient (β)	P value (n=109)
PGAP3	8.81±0.22	8.88±0.20	0.08	8.90±0.21	8.87±0.20	0.33	−0.84	0.57	−0.12	0.77
GSDMB	9.94±0.25	10.1±0.32	0.05	10.1±0.28	10.1±0.35	0.89	2.11	0.019	−0.81	0.0008
GSDMA	0.50±0.15	0.55±0.22	0.26	0.52±0.19	0.57±0.24	0.29	−1.40	0.27	0.14	0.69
Microarray (155 BEC) in the cross-sectional cohort
Gene	Asthma Susceptibility			Asthma Severity			ER or Hospitalization (last 12 months)
	Healthy Controls (n=27)	Asthma (n=128)	P value	Non-severe Asthma (n=78)	Severe Asthma (n=50)	P value	No (n=77)	Yes (n=47)	P value
PGAP3	10.8±0.22	10.8±0.33	0.43	10.8±0.34	10.8±0.31	0.63	10.8±0.35	10.8±0.29	0.57
GSDMB	10.5±0.42	10.4±0.47	0.15	10.4±0.45	10.4±0.51	0.23	10.3±0.46	10.5±0.49	0.03
GSDMA	6.26±0.15	6.21±0.13	0.02	6.21±0.14	6.21±0.12	0.56	6.21±0.13	6.20±0.13	0.41

Note: a general linear model was used to test the correlation between gene expression levels (natural logarithm transformed in the longitudinal cohort or log2 transformed in the cross-sectional cohort) and asthma phenotypes with adjustment of age, sex, race, BMI, and batch effect.